Carterra announced a research collaboration with AstraZeneca to develop hardware and software aimed at advancing lab-in-the loop drug discovery. The effort brings together scientific and technical expertise to connect laboratory systems, software and data infrastructure with artificial intelligence (AI)-driven discovery workflows. Lab-in-the-loop – the model in which AI systems propose drug candidates, wet-lab experiments generate data to test those predictions, and the resulting data feeds back to refine the next round of AI-guided design – is a growing area of interest to the pharmaceutical industry. A July 2026 Leerink Partners report described lab-in-the-loop as an emerging paradigm reshaping antibody discovery. A similar William Blair analysis pointed to the same shift as a driver of increased wet-lab data generation industry-wide. Many of the largest biopharma have described efforts to link AI models directly to autonomous laboratory experimentation.

Laverock Therapeutics has announces its in vivo programmes spanning CAR-T and genetic medicine. Building on the company’s progress in ex vivo cell therapies, the addition of in vivo programmes to its therapeutic pipeline expands Laverock’s ability to address some of the most significant challenges in oncology and genetic medicine. Laverock’s platform technology enables programmable, tunable and multiplex gene control for both endogenous targets and for transgenically expressed payloads. The platform has been validated across multiple cell therapy applications, including armoured autologous T cells and iPSC-derived macrophages targeting solid tumours. Laverock’s in vivo programmes will provide enhanced efficacy, safety, accessibility, and scalability for CAR-T, and allow the company to address indications with high unmet need in genetic medicine.

KURZ and ENERGYNEST officially inaugurated the new power-to-heat system at KURZ’s Sulzbach-Rosenberg site last week, together with project partners and representatives from government, industry and the local community. The system, which is already operating successfully, combines a 3MW electric heater with a thermal energy storage system, enabling KURZ to flexibly use renewable electricity to supply industrial process heat. With a storage capacity of 12MWh and 6 ENERGYNEST ThermalBattery modules, heat can be generated and stored when renewable electricity is available and supplied to production as needed. A directly connected ground-mounted photovoltaic system provides renewable electricity for the system. The power-to-heat solution generates more than 3,5GWh of process heat per year, covering more than 70% of the heat demand of one production line. At the same time, it reduces CO2 emissions by more than 700 metric tons annually.

Biotechnology company QUiCKR Bio is using liquid handling solutions from INTEGRA Biosciences to run its CRISPR edit confirmation assays. QUiCKR’s proprietary assays eliminate key bottlenecks of sequencing-based confirmation in CRISPR gene editing, ensuring more efficient workflows and accelerating downstream research. Quantifying the outcome of CRISPR gene editing to modify, delete or correct specific regions of DNA has traditionally been performed using costly and time-consuming NGS or droplet digital PCR (ddPCR). QUiCKR Bio, based in New York, offers pre-plated assays and cloud platform analysis for quantification of DNA sequences with NGS-level accuracy in just 20 minutes, helping pharma and biotech companies to optimise therapeutic candidates.

AbbVie announced that the Scottish Medicines Consortium (SMC) has accepted ELAHERE (mirvetuximab soravtansine) for use within NHS Scotland as a monotherapy for the treatment of eligible adults with folate receptor-alpha (FRα) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three lines of systemic treatment regimens. This marks an important milestone for the PROC community as it is the first treatment accepted for this population in NHS Scotland for over ten years.

The Kohler Lab at Umeå University, Sweden, uses liquid handling solutions from INTEGRA Biosciences to improve the efficiency of its Flexible Ageing Screening Technology (FAST) platform, which uses automated high throughput approaches to investigate aging and mitochondrial function. INTEGRA’s WELLJET reagent dispenser and the MINI 96 portable electronic pipette have become an integral part of the team’s high throughput workflows. The WELLJET is used to automatically fill plates, removing a major bottleneck previously performed using standard multichannel pipettes. The MINI 96 reformats samples between 96 and 384 well plates, and has automated the flow cytometry staining process.